Compare MQ & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MQ | HROW |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2021 | N/A |
| Metric | MQ | HROW |
|---|---|---|
| Price | $3.98 | $34.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $5.36 | ★ $71.14 |
| AVG Volume (30 Days) | ★ 4.6M | 924.6K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $624,884,000.00 | N/A |
| Revenue This Year | $17.47 | $44.68 |
| Revenue Next Year | $16.47 | $40.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.25 | N/A |
| 52 Week Low | $3.48 | $20.85 |
| 52 Week High | $7.04 | $54.98 |
| Indicator | MQ | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 27.80 |
| Support Level | $3.83 | $30.55 |
| Resistance Level | $4.94 | $40.64 |
| Average True Range (ATR) | 0.18 | 2.54 |
| MACD | 0.02 | -1.45 |
| Stochastic Oscillator | 50.86 | 2.31 |
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.